ATE392897T1 - Chinolinderivate als npy antagonisten - Google Patents
Chinolinderivate als npy antagonistenInfo
- Publication number
- ATE392897T1 ATE392897T1 AT03702533T AT03702533T ATE392897T1 AT E392897 T1 ATE392897 T1 AT E392897T1 AT 03702533 T AT03702533 T AT 03702533T AT 03702533 T AT03702533 T AT 03702533T AT E392897 T1 ATE392897 T1 AT E392897T1
- Authority
- AT
- Austria
- Prior art keywords
- quinoline derivatives
- npy antagonists
- npy
- antagonists
- quinoline
- Prior art date
Links
- SMWDFEZZVXVKRB-UHFFFAOYSA-N Quinoline Chemical class N1=CC=CC2=CC=CC=C21 SMWDFEZZVXVKRB-UHFFFAOYSA-N 0.000 title 1
- 239000005557 antagonist Substances 0.000 title 1
- 229940027991 antiseptic and disinfectant quinoline derivative Drugs 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/38—Nitrogen atoms
- C07D215/42—Nitrogen atoms attached in position 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/38—Nitrogen atoms
- C07D215/42—Nitrogen atoms attached in position 4
- C07D215/46—Nitrogen atoms attached in position 4 with hydrocarbon radicals, substituted by nitrogen atoms, attached to said nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Rheumatology (AREA)
- Endocrinology (AREA)
- Obesity (AREA)
- Immunology (AREA)
- Physical Education & Sports Medicine (AREA)
- Pain & Pain Management (AREA)
- Cardiology (AREA)
- Child & Adolescent Psychology (AREA)
- Emergency Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Heart & Thoracic Surgery (AREA)
- Urology & Nephrology (AREA)
- Nutrition Science (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Quinoline Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP02001967 | 2002-02-04 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE392897T1 true ATE392897T1 (de) | 2008-05-15 |
Family
ID=27635782
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT03702533T ATE392897T1 (de) | 2002-02-04 | 2003-01-27 | Chinolinderivate als npy antagonisten |
Country Status (19)
| Country | Link |
|---|---|
| US (1) | US6696467B2 (OSRAM) |
| EP (1) | EP1474145B1 (OSRAM) |
| JP (1) | JP4216196B2 (OSRAM) |
| KR (1) | KR100659428B1 (OSRAM) |
| CN (1) | CN100383124C (OSRAM) |
| AR (1) | AR038249A1 (OSRAM) |
| AT (1) | ATE392897T1 (OSRAM) |
| AU (1) | AU2003205679B2 (OSRAM) |
| BR (1) | BR0307441A (OSRAM) |
| CA (1) | CA2473181A1 (OSRAM) |
| DE (1) | DE60320529T2 (OSRAM) |
| ES (1) | ES2304498T3 (OSRAM) |
| MX (1) | MXPA04007502A (OSRAM) |
| PE (1) | PE20040120A1 (OSRAM) |
| PL (1) | PL372295A1 (OSRAM) |
| RU (1) | RU2298002C2 (OSRAM) |
| TW (1) | TW200400032A (OSRAM) |
| UY (1) | UY27646A1 (OSRAM) |
| WO (1) | WO2003066055A1 (OSRAM) |
Families Citing this family (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6900226B2 (en) * | 2000-09-06 | 2005-05-31 | Hoffman-La Roche Inc. | Neuropeptide Y antagonists |
| JP2004110367A (ja) * | 2002-09-18 | 2004-04-08 | Hitachi Ltd | 記憶装置システムの制御方法、記憶制御装置、および記憶装置システム |
| WO2005030754A1 (en) * | 2003-09-24 | 2005-04-07 | Janssen Pharmaceutica, N.V. | Indole or quinoline derivatives as non-pepticid npy y2 receptor inhibitors useful for the treatment of anxiolytic and depressive disorders and obesity |
| JP4869075B2 (ja) | 2003-11-19 | 2012-02-01 | アレイ バイオファーマ、インコーポレイテッド | Ｍｅｋの複素環阻害剤及びその使用方法 |
| EP1734963A4 (en) | 2004-04-02 | 2008-06-18 | Merck & Co Inc | METHOD FOR TREATING PEOPLE WITH METABOLIC AND ANTHROPOMETRIC DISORDER |
| JP2009510132A (ja) * | 2005-10-05 | 2009-03-12 | メルク フロスト カナダ リミテツド | ロイコトリエン生合成の阻害剤としての置換キノリン |
| RU2314295C2 (ru) * | 2006-03-01 | 2008-01-10 | Федеральное Государственное Образовательное Учреждение Высшего Профессионального Образования "Южный Федеральный Университет" | 2-гетарилзамещенные 1,3-трополона, способ их получения (варианты) и фармацевтическая композиция антимикробного действия |
| WO2008141077A1 (en) * | 2007-05-10 | 2008-11-20 | Janssen Pharmaceutica N.V. | Process for the preparation of tetrahydroquinolinyl, benzoxazine and benzothiazine derivatives |
| AU2008252636B2 (en) * | 2007-05-17 | 2013-10-31 | Helperby Therapeutics Limited | Use of 4-(pyrrolidin-1-yl)quinoline compounds to kill clinically latent microorganisms |
| WO2010056865A1 (en) * | 2008-11-14 | 2010-05-20 | Gilead Palo Alto, Inc. | Quinoline derivatives as ion channel modulators |
| CA2944788C (en) * | 2009-06-29 | 2023-08-22 | Agios Pharmaceuticals, Inc. | Compounds, and compositions thereof, which modulate pyruvate kinase m2, and methods of making same |
| KR20130129211A (ko) * | 2010-12-03 | 2013-11-27 | 다우 아그로사이언시즈 엘엘씨 | 에나민의 제조 방법 |
| US8865741B2 (en) | 2011-02-18 | 2014-10-21 | Asana Biosciences, Llc | Aminoindane compounds and use thereof in treating pain |
| MX2013015058A (es) | 2011-06-24 | 2014-01-20 | Amgen Inc | Antagonistas de melastatina 8 de potencial receptor transitorio y su uso en tratamientos. |
| EP2723717A2 (en) | 2011-06-24 | 2014-04-30 | Amgen Inc. | Trpm8 antagonists and their use in treatments |
| US8952009B2 (en) | 2012-08-06 | 2015-02-10 | Amgen Inc. | Chroman derivatives as TRPM8 inhibitors |
| WO2014028675A1 (en) | 2012-08-15 | 2014-02-20 | Endo Pharmaceuticals Inc. | Use of aminoindane compounds in treating overactive bladder and interstitial cystitis |
| KR102408261B1 (ko) | 2014-02-03 | 2022-06-10 | 비타이 파마슈티컬즈, 엘엘씨 | Ror-감마의 디하이드로피롤로피리딘 저해제 |
| US9663515B2 (en) | 2014-11-05 | 2017-05-30 | Vitae Pharmaceuticals, Inc. | Dihydropyrrolopyridine inhibitors of ROR-gamma |
| US10301261B2 (en) | 2015-08-05 | 2019-05-28 | Vitae Pharmaceuticals, Llc | Substituted indoles as modulators of ROR-gamma |
| EP3868750A1 (en) | 2015-11-20 | 2021-08-25 | Vitae Pharmaceuticals, LLC | Modulators of ror-gamma |
| TWI757266B (zh) | 2016-01-29 | 2022-03-11 | 美商維它藥物有限責任公司 | ＲＯＲ－γ調節劑 |
| PL3484865T3 (pl) | 2016-07-14 | 2023-01-09 | Crinetics Pharmaceuticals, Inc. | Modulatory somatostatyny i ich zastosowania |
| TWI774767B (zh) | 2017-05-12 | 2022-08-21 | 瑞士商多蒂孔股份有限公司 | 茚烷衍生物及其在有機電子產品的用途 |
| WO2019018975A1 (en) | 2017-07-24 | 2019-01-31 | Vitae Pharmaceuticals, Inc. | INHIBITORS OF ROR GAMMA |
| CN111225914B (zh) | 2017-07-24 | 2022-10-11 | 生命医药有限责任公司 | RORγ的抑制剂 |
| WO2019023278A1 (en) | 2017-07-25 | 2019-01-31 | Crinetics Pharmaceuticals, Inc. | MODULATORS OF SOMATOSTATIN AND USES THEREOF |
| JP7269917B2 (ja) * | 2017-08-17 | 2023-05-09 | イケナ オンコロジー， インコーポレイテッド | Ａｈｒ阻害剤およびその使用 |
| CA3088658A1 (en) * | 2018-01-17 | 2019-07-25 | Crinetics Pharmaceuticals, Inc. | Process of making somatostatin modulators |
| RU2702648C1 (ru) * | 2019-07-11 | 2019-10-09 | федеральное государственное автономное образовательное учреждение высшего образования «Южный федеральный университет» | 5,7-Ди(трет-бутил)-2-(4,7-дихлор-8-метил-5-нитрохинолин-2-ил)-4-нитро-1,3-трополон, обладающий цитотоксической активностью |
| SMT202500315T1 (it) | 2020-09-09 | 2025-11-10 | Crinetics Pharmaceuticals Inc | Formulazioni di un modulatore della somatostatina |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4035367A (en) * | 1974-09-09 | 1977-07-12 | Sandoz, Inc. | Hydroxyalkyl-substituted-amino-quinolines |
| CA1247547A (en) * | 1983-06-22 | 1988-12-28 | Paul Hadvary | Leucine derivatives |
| CA1328881C (en) | 1984-12-21 | 1994-04-26 | Pierre Barbier | Process for the manufacture of oxetanones |
| CA1270837A (en) | 1984-12-21 | 1990-06-26 | Hoffmann-La Roche Limited | Oxetanones |
| CA2035972C (en) | 1990-02-23 | 2006-07-11 | Martin Karpf | Process for the preparation of oxetanones |
| US5274143A (en) | 1991-07-23 | 1993-12-28 | Hoffmann-La Roche Inc. | Process for the preparation of (R)-3-hexyl-5,6-dihydro-4-hydroxy-6-undecyl-2H-pyran-2-one and (R)-5,6-dihydro-6-undecyl-2H-pyran-2,4(3H)-dione |
| CA2133620A1 (en) * | 1993-10-28 | 1995-04-29 | Werner Hofheinz | Aminoquinoline derivatives |
| RU2161967C2 (ru) * | 1994-08-18 | 2001-01-20 | Дзе Проктер Энд Гэмбл Компани | Соединения 7-(2-имидазолиниламино) хинолина, пригодные в качестве агонистов альфа-2-адренорецептора |
| US5552411A (en) * | 1995-05-26 | 1996-09-03 | Warner-Lambert Company | Sulfonylquinolines as central nervous system and cardiovascular agents |
| US6004996A (en) * | 1997-02-05 | 1999-12-21 | Hoffman-La Roche Inc. | Tetrahydrolipstatin containing compositions |
| US6267952B1 (en) | 1998-01-09 | 2001-07-31 | Geltex Pharmaceuticals, Inc. | Lipase inhibiting polymers |
| AU759388B2 (en) | 1998-08-14 | 2003-04-10 | Cheplapharm Arzneimittel Gmbh | Pharmaceutical compositions containing lipase inhibitors and chitosan |
| TR200100471T2 (tr) | 1998-08-14 | 2001-07-23 | F.Hoffmann-La Roche Ag | Lipaz inhibitörleri içeren farmasötik bileşimler |
| US6900226B2 (en) * | 2000-09-06 | 2005-05-31 | Hoffman-La Roche Inc. | Neuropeptide Y antagonists |
| DE10064105A1 (de) * | 2000-12-21 | 2002-06-27 | Bayer Ag | Neue Substituierte Imidazotriazinone |
| KR100621287B1 (ko) * | 2001-05-21 | 2006-09-13 | 에프. 호프만-라 로슈 아게 | 신경 펩타이드 ｙ 수용체에 대한 리간드로서의 퀴놀린유도체 |
-
2003
- 2003-01-27 WO PCT/EP2003/000777 patent/WO2003066055A1/en not_active Ceased
- 2003-01-27 RU RU2004126936/04A patent/RU2298002C2/ru not_active IP Right Cessation
- 2003-01-27 KR KR1020047012036A patent/KR100659428B1/ko not_active Expired - Fee Related
- 2003-01-27 PL PL03372295A patent/PL372295A1/xx not_active Application Discontinuation
- 2003-01-27 JP JP2003565479A patent/JP4216196B2/ja not_active Expired - Fee Related
- 2003-01-27 DE DE60320529T patent/DE60320529T2/de not_active Expired - Fee Related
- 2003-01-27 AT AT03702533T patent/ATE392897T1/de not_active IP Right Cessation
- 2003-01-27 AU AU2003205679A patent/AU2003205679B2/en not_active Ceased
- 2003-01-27 MX MXPA04007502A patent/MXPA04007502A/es active IP Right Grant
- 2003-01-27 BR BR0307441-2A patent/BR0307441A/pt not_active IP Right Cessation
- 2003-01-27 ES ES03702533T patent/ES2304498T3/es not_active Expired - Lifetime
- 2003-01-27 EP EP03702533A patent/EP1474145B1/en not_active Expired - Lifetime
- 2003-01-27 CN CNB038032805A patent/CN100383124C/zh not_active Expired - Fee Related
- 2003-01-27 CA CA002473181A patent/CA2473181A1/en not_active Abandoned
- 2003-01-30 TW TW092102218A patent/TW200400032A/zh unknown
- 2003-01-31 PE PE2003000111A patent/PE20040120A1/es not_active Application Discontinuation
- 2003-01-31 AR ARP030100304A patent/AR038249A1/es not_active Application Discontinuation
- 2003-02-03 UY UY27646A patent/UY27646A1/es not_active Application Discontinuation
- 2003-02-04 US US10/358,006 patent/US6696467B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| AU2003205679A1 (en) | 2003-09-02 |
| CN1627945A (zh) | 2005-06-15 |
| BR0307441A (pt) | 2005-01-04 |
| CN100383124C (zh) | 2008-04-23 |
| US20030153553A1 (en) | 2003-08-14 |
| MXPA04007502A (es) | 2004-11-10 |
| EP1474145B1 (en) | 2008-04-23 |
| JP2005523901A (ja) | 2005-08-11 |
| AR038249A1 (es) | 2005-01-05 |
| US6696467B2 (en) | 2004-02-24 |
| EP1474145A1 (en) | 2004-11-10 |
| DE60320529T2 (de) | 2009-06-10 |
| KR100659428B1 (ko) | 2006-12-19 |
| PE20040120A1 (es) | 2004-03-06 |
| PL372295A1 (en) | 2005-07-11 |
| JP4216196B2 (ja) | 2009-01-28 |
| RU2004126936A (ru) | 2005-10-10 |
| ES2304498T3 (es) | 2008-10-16 |
| CA2473181A1 (en) | 2003-08-14 |
| DE60320529D1 (de) | 2008-06-05 |
| TW200400032A (en) | 2004-01-01 |
| UY27646A1 (es) | 2003-08-29 |
| KR20040081484A (ko) | 2004-09-21 |
| AU2003205679B2 (en) | 2006-06-29 |
| RU2298002C2 (ru) | 2007-04-27 |
| WO2003066055A1 (en) | 2003-08-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE392897T1 (de) | Chinolinderivate als npy antagonisten | |
| ATE461191T1 (de) | N-substituierte 2-oxodihydropyridinderivate als npy antagonisten | |
| IS8439A (is) | Nýjar kínólín afleiður | |
| DE50304983D1 (de) | Heteroaryloxy-substituierte phenylaminopyrimidine als rho-kinaseinhibitoren | |
| DE60330694D1 (de) | Pyrimidopyrimidone als kinaseinhibitoren | |
| DE602004015724D1 (de) | Diazepinoindolderivate als kinaseinhibitoren | |
| ATE529421T1 (de) | Chinolinderivate als phosphodiesterase-hemmer | |
| ATE341543T1 (de) | Pyridinoylpiperidine als 5-ht1f agonisten | |
| DE60110844D1 (de) | Chinazolone derivate als alfa 1a/b adrenozeptor antagonisten | |
| ATE506360T1 (de) | Neue benzimidazolderivate | |
| ATE384053T1 (de) | Triazolderivate als tachykininrezeptor- antagonisten | |
| DE60317365D1 (de) | Substituierte 4-alkoxyoxazol derivate als ppar agonisten | |
| NO20041235L (no) | Kinolinderivater som neuropeptid Y antagonister | |
| DE602004019555D1 (de) | Heterocyclische 7-aminoalkylidenylchinolone und -naphthyridone | |
| DE602004004278D1 (de) | 4-cycloalkylaminopyrazolopyrimidin als nmda/nr2b-antagonisten | |
| DE60316411D1 (de) | Thiazolderivate als npy-rezeptorantagonisten | |
| DE60203529D1 (de) | Indolderivate als cox-ii-inhibitoren | |
| NL1027084A1 (nl) | Gesubstitueerde triazoolderivaten als oxytocine-antagonisten. | |
| ATE428420T1 (de) | Substituierte 8-arylchinoline als phosphodiesterase-4-hemmer | |
| DE602004004295D1 (de) | 6-ä(substituiertes)phenylütriazolopyrimidine als antikrebsmittel | |
| ATE309994T1 (de) | Alkoxycarbonylaminobenzoesäure- oder alkoxycarbonylaminotetrazolylphenylderivate als ip-antagonisten | |
| ATE394372T1 (de) | G-lactamderivate als prostaglandinagonisten | |
| ATE418542T1 (de) | Als ccr5-antagonisten verwendbare aryloxim- piperazine | |
| ATE462688T1 (de) | Diarylsulfone als 5-ht2a-antagonisten | |
| NO20041958L (no) | Stovtett plagg |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |